Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Grant H Skrepnek. (2005) Cost–effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. Expert Review of Pharmacoeconomics & Outcomes Research 5:5, pages 603-623.
Read now
Read now
Articles from other publishers (5)
Tong Zhu, Walid M. Awni, Balakrishna Hosmane, Maureen T. Kelly, Darryl J. Sleep, James C. Stolzenbach, Katty Wan, Titus O. Chira & Rajendra S. Pradhan. (2009) ABT-335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans. The Journal of Clinical Pharmacology 49:1, pages 63-71.
Crossref
Crossref
Menno Knetsch. 2008. Biomaterials Fabrication and Processing Handbook. Biomaterials Fabrication and Processing Handbook
505
534
.
Barry Smith, Radha Gholkar, Mark Mann & Nancy Toward. 2006. Caffeine and Activation Theory. Caffeine and Activation Theory
93
131
.
Aman U Buzdar & John FR Robertson. (2016) Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer. Annals of Pharmacotherapy 40:9, pages 1572-1583.
Crossref
Crossref
Haruki Musha, Akio Hayashi, Keisuke Kida, Eiji Takahashi, Kae Suzuki, Kensuke Kawasaki, Koji Inoue, Yoshihiro Akashi, Katsuhiko Tsuchiya, Masahiro Yamauchi, Tomoyuki Kunishima & Nobuyuki Hashimoto. (2006) Gender Difference in the Level of Highdensity Lipoprotein Cholesterol in Elderly Japanese Patients with Coronary Artery Disease. Internal Medicine 45:5, pages 241-245.
Crossref
Crossref